News

Filter

Current filters:

IluvienpSivida

1 to 9 of 10 results

pSivida’s Iluvien given marketing authorization in Norway and reimbursement approval in Portugal

pSivida’s Iluvien given marketing authorization in Norway and reimbursement approval in Portugal

29-07-2014

Eye disease specialist pSivida has been granted marketing authorization in Norway for its treatment Iluvien,…

IluvienNorwayOphthalmicsPharmaceuticalPortugalpSividaRegulation

pSivida’s marketing authorizations for Iluvien in 10 countries reaches next stage

pSivida’s marketing authorizations for Iluvien in 10 countries reaches next stage

01-07-2014

Drug delivery specialists pSivida says that the regulatory process for marketing authorizations of Iluvien…

EuropeIluvienOphthalmicsPharmaceuticalpSividaRegulation

Alimera says FDA advisory committee on Iluvien no longer necessary

Alimera says FDA advisory committee on Iluvien no longer necessary

19-12-2013

US ophthalmic pharma specialist Alimera Sciences has entered into labeling discussions with the US Food…

Alimera SciencesIluvienNorth AmericaOphthalmicsPharmaceuticalpSividaRegulation

FDA calls for new trial before it can approve Alimera’s Iluvien

FDA calls for new trial before it can approve Alimera’s Iluvien

18-10-2013

USA-based ophthalmic biopharma specialist Alimera Sciences says that it has received a third Complete…

Alimera SciencesIluvienNorth AmericaOphthalmicsPharmaceuticalpSividaRegulation

UK’s NICE recommends Iluvien for DME

02-10-2013

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has published final draft…

Alimera SciencesEuropeIluvienOphthalmicsPharmaceuticalpSividaRegulation

pSivida and Alimera's Iluvien debuts in Germany; New data on Novartis' Lucentis

08-05-2013

USA-based pSivida Corp (Nasdaq: PSDV), a leader in developing sustained release, drug delivery products…

Alimera SciencesIluvienLucentisMarkets & MarketingNovartisOphthalmicsPharmaceuticalpSividaResearch

Another FDA rejection for Alimera’s DME drug Iluvien

14-11-2011

Shares of US ophthalmic drug develop Alimera Sciences (Nasdaq: ALIM) plunged nearly 73% to $2 on Friday,…

Alimera SciencesIluvienNorth AmericaOphthalmicsPharmaceuticalpSividaRegulation

Alimera resubmits eye drug Iluvien to US regulator

17-05-2011

USA-based Alimera Sciences (Nasdaq: ALIM) says that it has resubmitted its New Drug Application for Iluvien…

Alimera SciencesIluvienNorth AmericaOphthalmicsPharmaceuticalpSividaRegulation

1 to 9 of 10 results

COMPANY SPOTLIGHT

Menarini

Back to top